South Korea Pharmaceuticals: key facts

Last updated 2026-11-11 · 9 sourced answers from KIRA RESEARCH reports and field research. Every figure shows its year and source.

Market size

How much bioreactor capacity does Samsung Biologics have in Songdo?

Samsung Biologics' Songdo plants 1-5 hold 785k L of bioreactor capacity, according to KIRA's 2026 market report (SBL FY25).

Source: SBL FY25, 2025 · KIRA report: Korea pharma 2027 — biosimilars go global, the CDMO capacity build compounds

How big is South Korea's domestic pharma market?

Domestic pharma is a slow-growing base of about USD 23 bn in 2025, on a trajectory of about 2.4%, according to KIRA's 2026 market report (Korea Pharma Outlook 2025).

Source: Korea Pharma Outlook 2025, 2025 · KIRA report: Korea pharma 2027 — biosimilars go global, the CDMO capacity build compounds

How large were South Korea's pharmaceutical exports in 2025?

South Korea's pharmaceutical exports reached USD 10.4 bn in 2025, up 11.8% year on year, with biologics at 62.6% of the total, according to KIRA's 2026 market report (KPBMA 2026).

Source: KPBMA 2026, 2025 · KIRA report: Korea pharma 2027 — biosimilars go global, the CDMO capacity build compounds

Growth

What does KIRA forecast for South Korea's medicine exports in 2027?

KIRA's forecast puts South Korean medicine exports at USD 12.8 bn in 2027, up from USD 10.4 bn in 2025, according to KIRA's 2026 market report (KIRA triangulation of KPBMA and Korea Customs data).

Source: Kira estimates, 2027 · KIRA report: Korea pharma 2027 — biosimilars go global, the CDMO capacity build compounds

What revenue and new orders did Samsung Biologics report in 2025?

Samsung Biologics reached KRW 4.56 trn of revenue and KRW 6 trn of new orders in 2025, according to KIRA's 2026 market report (SBL FY25).

Source: SBL FY25, 2025 · KIRA report: Korea pharma 2027 — biosimilars go global, the CDMO capacity build compounds

Key players

How many FDA biosimilar approvals did Korean companies win in 2025?

Korean companies won 5 of 18 US FDA biosimilar approvals in 2025, the most of any country, led by Celltrion and Samsung Bioepis, according to KIRA's 2026 market report (MDToday 2026).

Source: MDToday 2026, 2025 · KIRA report: Korea pharma 2027 — biosimilars go global, the CDMO capacity build compounds

Regulation

What does the third five-year bio plan target by 2030?

The third five-year bio plan targets doubled bio exports and three blockbuster drugs by 2030, according to KIRA's 2026 market report.

Source: KIRA research, 2030 · KIRA report: Korea pharma 2027 — biosimilars go global, the CDMO capacity build compounds

How does the BIOSECURE Act affect Korean contract manufacturers?

The BIOSECURE Act, signed into the FY26 NDAA, redirects US demand that Chinese CDMOs lose to Korean plants, according to KIRA's 2026 market report (Lawtimes 2026).

Source: Lawtimes 2026, 2026 · KIRA report: Korea pharma 2027 — biosimilars go global, the CDMO capacity build compounds

Who's who

active pharmaceutical ingredients

27 companies in BizDirect Asia's database. Supplier list · Manufacturer list · Distributor list

Top regions: Gyeonggi (7), Seoul (3), Jeju (1), Jeonbuk (1)

pharmaceutical raw materials

8 companies in BizDirect Asia's database. Distributor list

Top regions: Seoul (4)

Company data: BizDirect Asia (sister company)